What is FIB-4?
The Fibrosis-4 (FIB-4) index is a non-invasive biomarker panel used to estimate the degree of liver fibrosis (scarring) in patients with chronic liver disease. It was originally developed and validated by Sterling et al. in 2006 in a cohort of patients co-infected with HIV and hepatitis C virus (HCV), but has since been widely validated for use in various chronic liver diseases including non-alcoholic fatty liver disease (NAFLD), hepatitis B, and alcoholic liver disease.
The FIB-4 index combines four readily available clinical variables: patient age, serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), and platelet count. By integrating these parameters into a single score, FIB-4 provides clinicians with a quick and cost-effective method for stratifying patients into low-risk and high-risk categories for advanced fibrosis, defined as Metavir stages F3 and F4 (bridging fibrosis and cirrhosis).
The primary advantage of FIB-4 over invasive procedures is that it uses routine laboratory tests that are already part of standard clinical assessments. This makes it an ideal first-line screening tool in primary care and hepatology settings. Many international guidelines, including those from the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), recommend FIB-4 as an initial assessment tool for liver fibrosis.
FIB-4 Formula
The FIB-4 index is calculated using the following formula:
Where:
- Age is measured in years
- AST (Aspartate Aminotransferase) is measured in U/L
- ALT (Alanine Aminotransferase) is measured in U/L
- Platelet Count is measured in ×10&sup9;/L (equivalent to ×10³/µL)
The mathematical rationale behind this formula involves several physiological relationships. AST tends to rise with progressive liver damage. Platelet count decreases as fibrosis worsens because the scarred liver produces less thrombopoietin and sequesters more platelets. Age is included because older patients are more likely to have accumulated fibrosis over time. The square root of ALT serves as a normalizing factor that accounts for the degree of hepatic inflammation.
Interpreting Your FIB-4 Score
| FIB-4 Score | Risk Level | Interpretation | Recommended Action |
|---|---|---|---|
| < 1.30 | Low Risk | Advanced fibrosis excluded (NPV ~90%) | Reassess in 1–3 years if risk factors persist |
| 1.30 – 2.67 | Indeterminate | Cannot reliably rule in or rule out fibrosis | Further testing: elastography, ELF test, or specialist referral |
| > 2.67 | High Risk | Advanced fibrosis likely (PPV ~65%) | Hepatology referral, consider liver biopsy or elastography |
It is important to understand the concept of negative predictive value (NPV) and positive predictive value (PPV) in the context of FIB-4. At the lower cutoff of 1.30, FIB-4 has an NPV of approximately 90%, meaning that 90% of patients scoring below this threshold truly do not have advanced fibrosis. Conversely, at the upper cutoff of 2.67, the PPV is approximately 65%, meaning that about two-thirds of patients above this threshold actually have advanced fibrosis. The indeterminate zone between these cutoffs captures patients who require additional evaluation.
For patients aged 65 and older, some experts recommend adjusting the lower cutoff to 2.0 to maintain diagnostic accuracy, as the age component of the formula can artificially inflate scores in elderly patients without significant liver disease.
APRI Score Comparison
The AST to Platelet Ratio Index (APRI) is another non-invasive fibrosis marker that uses only AST and platelet count. The formula is:
The upper limit of normal (ULN) for AST is typically set at 40 U/L. APRI is simpler to calculate but generally considered less accurate than FIB-4 for detecting advanced fibrosis.
| Feature | FIB-4 | APRI |
|---|---|---|
| Variables | Age, AST, ALT, Platelets | AST, Platelets |
| Accuracy (AUROC) | 0.80 – 0.87 | 0.75 – 0.83 |
| Low-risk cutoff | < 1.30 | < 0.5 |
| High-risk cutoff | > 2.67 | > 1.5 |
| Best for | NAFLD, HCV, HBV | HCV (WHO recommended) |
| Guideline endorsement | AASLD, EASL, AGA | WHO (for HCV in resource-limited settings) |
FIB-4 vs. Liver Biopsy
Liver biopsy has traditionally been considered the gold standard for assessing hepatic fibrosis. During a biopsy, a small sample of liver tissue is extracted and examined histologically. However, biopsy has several significant drawbacks:
- Invasiveness: The procedure carries risks of pain (20–30% of patients), bleeding (0.5%), and rarely death (0.01%)
- Sampling error: A biopsy examines only about 1/50,000th of the liver, leading to potential misclassification of fibrosis stage in up to 25% of cases
- Inter-observer variability: Pathologists may disagree on fibrosis staging in 10–20% of specimens
- Cost and inconvenience: Requires trained personnel, imaging guidance, and patient recovery time
FIB-4 addresses many of these limitations by providing a rapid, reproducible, and virtually free assessment using readily available blood tests. While FIB-4 cannot replace biopsy in all situations, it serves as an excellent triage tool that can reduce the number of unnecessary biopsies by 30–50%. Current practice guidelines recommend using FIB-4 as a first-line assessment, with biopsy or transient elastography reserved for patients in the indeterminate zone or those with discordant results.
When to Use FIB-4
FIB-4 is most appropriately used in the following clinical scenarios:
- NAFLD/NASH screening: For patients with metabolic risk factors (obesity, type 2 diabetes, metabolic syndrome) to determine who needs specialist referral
- Chronic hepatitis C: Before and after antiviral treatment to assess baseline fibrosis and treatment response
- Chronic hepatitis B: As part of routine monitoring alongside viral load and liver function tests
- Alcoholic liver disease: To screen patients with chronic alcohol use for significant fibrosis
- Primary care triage: As a first-line tool to identify patients who need hepatology referral versus those who can be managed in primary care
FIB-4 is best used as a screening or triage tool rather than a definitive diagnostic test. Patients identified as high-risk should undergo confirmatory testing, and treatment decisions should not be based solely on FIB-4 results.
Limitations
- Age dependency: FIB-4 may overestimate fibrosis risk in patients over 65 years old and underestimate it in younger patients, as age is directly included in the formula
- Not validated for all populations: The original validation cohort was predominantly male with HIV/HCV co-infection. Performance may differ in other populations
- Cannot distinguish fibrosis stages: FIB-4 is designed to detect advanced fibrosis (F3–F4) but cannot differentiate between mild (F1) and moderate (F2) fibrosis
- Confounders: Conditions affecting AST, ALT, or platelets (e.g., muscle disease, hemolytic conditions, bone marrow disorders) can produce misleading results
- Indeterminate zone: Approximately 30–50% of patients fall into the indeterminate range (1.30–2.67), requiring additional testing
- Snapshot in time: FIB-4 reflects current laboratory values and does not capture the dynamic nature of fibrosis progression or regression
Frequently Asked Questions
Is FIB-4 accurate for diagnosing liver fibrosis?
FIB-4 has good accuracy for ruling out advanced fibrosis (F3–F4), with a negative predictive value of approximately 90% at the lower cutoff of 1.30. Its area under the receiver operating characteristic curve (AUROC) ranges from 0.80 to 0.87 depending on the population studied. However, it is a screening tool and should be used in conjunction with clinical assessment and, when indicated, confirmatory imaging or biopsy.
Can I use FIB-4 if I am under 35 years old?
FIB-4 was validated in patients aged 35 and older. In younger patients, the age component may lead to artificially low scores that could underestimate fibrosis risk. If you are under 35 with risk factors for liver disease, your clinician may prefer alternative assessments such as transient elastography or the Enhanced Liver Fibrosis (ELF) test.
How often should FIB-4 be recalculated?
For patients at risk of liver disease, guidelines recommend recalculating FIB-4 every 1 to 3 years if the initial result is in the low-risk category. Patients in the indeterminate or high-risk categories should be evaluated more frequently and referred for additional testing. After therapeutic interventions (e.g., antiviral treatment, lifestyle changes), FIB-4 can be used to monitor response over time.
What is the difference between FIB-4 and FibroScan?
FibroScan (transient elastography) is a non-invasive imaging technique that measures liver stiffness using ultrasound waves. It provides a direct physical measurement of liver stiffness in kilopascals (kPa), which correlates with fibrosis stage. FIB-4, on the other hand, is a blood test-based index. The two are complementary: FIB-4 is typically used as a first-line screening tool, and FibroScan is used as a second-line confirmatory test for patients in the indeterminate zone.
Does FIB-4 work for fatty liver disease (NAFLD)?
Yes, FIB-4 has been extensively validated for NAFLD and is recommended by the AASLD and AGA as a first-line assessment tool for liver fibrosis in NAFLD patients. It is particularly useful for identifying which patients with NAFLD have advanced fibrosis and require specialist referral, helping to manage the large number of patients with this increasingly common condition. Studies show that FIB-4 performs well in NAFLD populations with AUROC values of 0.80–0.85 for detecting advanced fibrosis.